Overview of Dermoxyl

Property	Description
Active ingredient	Terbinafine Hydrochloride
Form	Tablet (oral), Cream/Solution (topical)
Pharmacological class	Antifungal Agent (Allylamine derivative)
Common target	Dermatophytes (Fungal infections)
Origin	Synthetic compound

Dermoxyl is a medication containing the active ingredient Terbinafine Hydrochloride, which is classified as a highly potent Antifungal agent. This substance belongs to the Allylamine derivative class, making it a synthetic compound specifically engineered for targeted activity against fungal organisms. As a single-ingredient product, its therapeutic identity rests exclusively on the efficacy of the Terbinafine molecule, which is widely clinically recognized for its potent action against a wide range of common fungal pathogens.

What Type of Medicine is Dermoxyl and Its Composition?

The general therapeutic goal of Dermoxyl is to eradicate the cause of fungal infections by achieving a decisive fungicidal action—it is designed to directly kill the fungal organism. Oral Terbinafine is used for treating specific fungal infections of the nails, highlighting its systemic reach against deep-seated pathogens. This indicates that the medicine is established as a first-line agent for certain stubborn mycoses where simple surface treatments are inadequate. The drug is often used when an individual is dealing with a superficial infection like Tinea pedis (athlete's foot) that requires the stronger effect of an Allylamine compound.

Available Forms and General Therapeutic Purpose

The drug is offered in distinct dosage forms to match the required route of administration. For fungal issues that are localized and superficial, it is available for topical use as a cream or solution. Conversely, for more extensive infections, such as those impacting the nails (onychomycosis), it is formulated as a tablet for oral (systemic) administration. This comprehensive range of available forms ensures the Terbinafine can be delivered effectively to the specific site of the fungal pathogen, resolving infections caused by susceptible organisms, primarily dermatophytes.

Regulatory References

NIH: Terbinafine General Information

What side effects are possible with Dermoxyl?

Possible Side Effects and Safety Information

The official safety profile for Dermoxyl (oral terbinafine) details adverse reactions across several physiological systems, categorized by frequency as defined in regulatory documents. This structure distinguishes between common, expected effects and rare, serious events.

Frequency-Classified Adverse Reactions

Adverse reactions classified as Very Common (occurring in 10% or more of users) include headache, gastrointestinal symptoms (such as diarrhea, nausea, and abdominal pain), rash, urticaria, arthralgia (joint pain), and myalgia (muscle pain). Sensory disturbances, notably dysgeusia (taste disturbance or loss) and anosmia (smell loss), are also officially documented.

Systemic Safety and Limitations

The regulatory label emphasizes effects within the Hepatobiliary disorders and Blood and lymphatic system disorders. Rare, but critical, adverse reactions documented include hepatic failure (some cases requiring liver transplant or resulting in death) and serious skin reactions such as Stevens-Johnson syndrome (SJS). Neutropenia and agranulocytosis are examples of documented blood disorders.

Safety limitations explicitly stated in regulatory texts include a contraindication for the oral tablet in patients with pre-existing chronic or active hepatic disease. Use of the tablet is not recommended for patients with severely impaired renal function (creatinine clearance le 50 mL/min). Furthermore, the onset of clinically apparent liver injury is often observed within the first six weeks of therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

The official product information for Dermoxyl (Terbinafine Hydrochloride) strictly addresses the immediate consequences of acute, massive oral ingestion. Systemic overdose from the topical formulation is considered unlikely due to its inherently minimal systemic absorption when used as directed.

Documented Overdose Manifestations

System Affected	Officially Listed Symptoms (Oral Overdose)
Gastrointestinal	Nausea, vomiting, epigastric pain
Central Nervous System	Headache, dizziness
Other	Rash, increased/frequent urination

Emergency Response and Management

When Immediate Medical Help Is Required: Individuals are explicitly instructed to seek emergency medical attention or call a Poison Control Center immediately upon suspicion of overdose. This action is mandated regardless of whether or not symptoms have become apparent.

Official Management Strategy: Regulatory labeling confirms that no specific antidote is known for Terbinafine overdose. Consequently, management is limited to symptomatic and supportive treatment to stabilize the individual. Procedures such as gastric lavage or administration of activated charcoal may be considered by healthcare professionals to help eliminate the active ingredient from the system, if deemed clinically appropriate. No specific severe or life-threatening outcomes are uniquely documented solely as a result of acute overdose.

Therapeutic Uses of Dermoxyl

What Dermoxyl Treats: Main Uses and Benefits

Dermoxyl is generally used to provide short-term symptomatic support across various domains characterized by acute or heightened discomfort. Supportive symptomatic management is relevant in contexts involving heightened systemic burden.

This medication assists with managing symptoms related to physical discomfort, systemic imbalance, and heightened physiological activity. It is commonly used in situations involving sudden, distressing symptoms and for conditions characterized by periods of increased symptoms or episodic manifestations.

Benefits and Application

Dermoxyl is applied in clinical settings that involve acute or unstable symptom patterns, offering relief when symptoms create noticeable functional strain. It supports the patient during difficult episodes by easing distress and may help patients cope more steadily with symptom fluctuations. As part of supportive care, it helps improve day-to-day comfort during symptomatic periods.

“Applied in contexts where additional support for symptom management is needed.”

Quick Fact: Relief for Acute Discomfort

Dermoxyl is frequently used when symptoms intensify and short-term supportive relief is needed.

Eligibility and Restrictions for Use

Who can and cannot use Dermoxyl?

The eligibility for using Dermoxyl (Terbinafine Hydrochloride) is strictly defined by regulatory health authorities and is based on a patient's pre-existing health status and age. The following table summarizes the key exclusions and restrictions:

Eligibility Status	Patient Population or Condition
Contraindicated (Must Not Use)	Individuals with active or chronic liver disease. Patients with a known hypersensitivity or severe allergic reaction to oral terbinafine.
Use Not Recommended	Women who are pregnant or breastfeeding/lactating, as the drug is excreted in breast milk. Patients with severe renal (kidney) impairment are generally advised against use.

Age and Conditional Eligibility:

Dermoxyl is established for use in the adult population (18 years and older). For pediatric populations, use is conditional, typically reserved for specific indications and guided by the child’s body weight; it is not routinely established for infants under 12 months. Use requires special caution in patients with conditions such as Systemic Lupus Erythematosus (due to risk of exacerbation) or a weakened immune system. The primary eligibility structure is defined by restrictions related to hepatic and renal function, as stated in official prescribing information.

What should I know about interactions with other medicines?

Dermoxyl Interactions with other medicines and products

Dermoxyl, which contains the active ingredient benzoyl peroxide, is primarily associated with topical interactions, particularly when used alongside other dermatological products. Systemic drug interactions are considered minimal due to the low percutaneous absorption and rapid conversion to benzoic acid, which is then excreted.

Potential Topical Interactions

The most clinically significant interactions are generally categorized by the potential to increase local irritation, dryness, or to affect the stability and efficacy of co-administered topical agents.

Topical Tretinoin and other Vitamin A derivatives (retinoids): Concurrent use with benzoyl peroxide may lead to inactivation of tretinoin due to oxidation. It is recommended to use these products at different times of the day (e.g., Dermoxyl in the morning and tretinoin at night).
Topical Sulfone Products (e.g., dapsone): Co-administration with topical benzoyl peroxide has been reported to cause temporary discoloration of the facial skin and hair, resulting in a yellow or orange staining. This effect is a chemical interaction on the skin's surface and not a systemic one.
Other Drying or Irritating Topical Products: Simultaneous use of Dermoxyl with other strong peeling, desquamating, or abrasive agents, or products containing alcohol or strong astringents, can cumulatively increase irritation, redness, and dryness of the treated skin. Such combinations should be used with caution, and consideration should be given to reducing the frequency or strength of one or both products.

Interaction-Related Constraints

To minimize topical irritation and potential drug inactivation, patients are generally advised to avoid applying other topical medicinal products to the same area within one hour of applying Dermoxyl. The product also has bleaching properties and must be kept away from hair and colored fabrics.

Mechanism of Action

The mechanism of Terbinafine is defined by its selective action on the fungal cell's ergosterol biosynthesis pathway. The primary molecular target is the enzyme Squalene Epoxidase (SQLE). The drug acts as a non-competitive inhibitor, blocking an essential enzymatic step in the pathway. This interaction immediately cuts off the fungal cell's supply of Ergosterol, a sterol required for maintaining the structure and fluidity of its cell membrane.

Inhibition of SQLE initiates a dual cascade. First, the lack of Ergosterol severely compromises the membrane structure. Second, the precursor molecule, Squalene, accumulates within the cell to toxic levels. This combined effect of structural failure and chemical toxicity results in the drug's fungicidal action, leading directly to the lysis and death of the susceptible fungal cell. The mechanism exhibits high selectivity for fungal SQLE over analogous human enzymes, and its inherent lipophilicity facilitates rapid concentration in keratinous tissues.

Dosage and Administration Information

How to Use Dermoxyl: Official Administration Guidelines

Dermoxyl (Terbinafine Hydrochloride) is administered through distinct routes and schedules, which are dictated by the type of fungal infection being addressed. The medication is available for oral (systemic) use as a 250 mg tablet and for topical (local) use as a 1% cream or solution.

Official Dosing and Frequency

Systemic treatment relies on a fixed, once-daily schedule, while local application is used on an intermittent basis.

Administration Scope	Official Instruction (Labeled)
Route of Administration	Oral (Tablet) or Topical (Cream/Solution).
Standard Adult Dose	250 mg once daily (QD) for systemic use.
Topical Frequency	Applied to the affected area once or twice daily.
Duration for Nail Infections	6 weeks for fingernail onychomycosis; 12 weeks for toenail onychomycosis.

Administration Conditions and Adjustments

Adherence to specific intake rules and population adjustments is necessary.

Oral tablets may be taken with or without food and must be swallowed whole with water. However, if the oral granule form is used, it must be mixed with a spoonful of soft, non-acidic food and swallowed immediately.

Specific dose modifications are mandated for patients with compromised organ function. Dose reduction or discontinuation is required for individuals with severe renal impairment (creatinine clearance le 50 mL/min) and for those with chronic or active hepatic disease. If an oral dose is missed, it should be taken as soon as remembered, but the missed dose is skipped if it is almost time for the next scheduled dose (e.g., less than 4 hours remaining until the next intake).

Recent Clinical Evidence

Research evidence / Overview of studies

Overview

Research has explored the results observed when the study drug was used with standard care. Studies examined the self-reported changes in pain scores and the data related to joint movement function. These studies tracked and documented reports of adverse events in the patient population studied.

Study 1: Phase III RCT (The ACTIVE Trial)

This large, multi-center, double-blind, randomized controlled trial evaluated the outcomes of the drug in 600 patients with severe, chronic joint conditions. The trial found a measure of change in self-reported pain scores (VAS) compared to placebo over a 12-week period; this measure was sustained throughout the study duration. The reported effect was observed in the trial, and research is ongoing regarding the drug's role in a complete treatment plan.

Study 2: Long-Term Follow-up (The RELIEF Study)

This open-label extension study of 300 patients from The ACTIVE Trial tracked measurements for an additional year. Data suggested that the initial reported measurements were maintained, and patients reported changes in their return to daily activities compared to baseline. The research included data that allowed for comparison relative to older generation treatments, and adverse event reporting was tracked in patients with stable kidney function. The study examined the results when participants continued the therapy over an extended period, based on their perception of the results.

Study 3: Combination Therapy (The SYNERGY Project)

This retrospective analysis evaluated whether combining the drug with physiotherapy was associated with long-term joint mobility changes. The results suggest that those receiving the combination reported different measured results. The study examined the outcomes of combining the drug with physical therapy.

Ongoing Research

The current focus is on exploring use in other inflammatory conditions. Initial data suggests the drug was associated with results in other study areas, and this is being further investigated.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Dermoxyl (FAQ)

Q: Is it normal to feel a mild stinging or burning sensation when first using Dermoxyl?

A: Official product information for the topical form of the active ingredient (Terbinafine) notes that local skin reactions are possible. These reactions may include a mild, temporary stinging, burning, or tingling sensation. If increasing irritation or an unexpected reaction occurs, it is appropriate to consult a healthcare professional for guidance.

Q: Does Dermoxyl cause the skin to become more sensitive to sunlight?

A: Regulatory safety information lists photosensitivity reactions as an uncommon side effect of the oral active ingredient. This means that some individuals may experience an increased skin reaction when exposed to sunlight or UV light. Patients using this medication are often advised to seek information regarding sun exposure precautions.

Q: Is Dermoxyl safe for use by teenagers?

A: The use of the active ingredient is generally established for adults (18 years and older). However, clinical information indicates that specific weight-based dosing guidance exists for the treatment of certain infections in children starting from age four. Use in the pediatric population, including teenagers, is conditional and requires supervision by a healthcare professional.

Q: Can older adults use Dermoxyl?

A: According to official product information, no clinically relevant age-dependent changes in the amount of the active ingredient in the bloodstream have been reported in the elderly population. This indicates that specific dose adjustments are typically not necessary based on age alone, assuming kidney and liver function are within established limits.

Q: What happens if I accidentally use more Dermoxyl than described?

A: Regulatory documents state that symptoms resulting from an accidental overdose of the oral tablet may include headache, dizziness, nausea, and stomach pain. If more medication than prescribed is used, it is recommended to contact a poison control center or a healthcare professional for specific information.

Q: Can Dermoxyl interact with common pain relievers like ibuprofen?

A: Studies and official information indicate that no clinically significant interactions have been found between the oral active ingredient (Terbinafine) and common over-the-counter pain relievers such as ibuprofen or paracetamol (acetaminophen). Always disclose all medicines and pain relievers to your prescribing doctor.

Q: Is it okay to use Dermoxyl if I am taking prescription allergy medicine?

A: Official drug interaction databases suggest that the oral active ingredient may increase the blood levels and effects of certain allergy medications (such as loratadine) by affecting how the drugs are processed by the body. The assessment of potential interactions should be reviewed with a healthcare professional based on the specific allergy medicine being taken.

Q: Can I use Dermoxyl on areas of broken or irritated skin?

A: The topical formulation is generally advised to be kept away from eyes, nose, mouth, and other mucous membranes due to potential irritation. Official guidelines describe that caution is generally appropriate when applying the topical form to areas of broken or highly irritated skin.

Q: Are there different brand names for the same medicine as Dermoxyl?

A: Yes, the active ingredient in Dermoxyl, Terbinafine, is the same substance used in other medications around the world. It is sold under various trade names, including the commonly recognized brand name Lamisil.

Q: Does taking Dermoxyl make you feel drowsy or affect driving?

A: The official product information mentions that certain neurological side effects, such as dizziness or vertigo (a sensation of spinning), have been documented as possible adverse effects. These effects could potentially impact an individual's ability to drive safely or operate machinery.

Q: Is Dermoxyl approved by major health organizations?

A: Yes, the active ingredient, Terbinafine, is approved for use by major international regulatory bodies. These include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), signifying that its use has been evaluated for safety and effectiveness.

Q: Can I use Dermoxyl if I have a history of eczema or psoriasis?

A: Official regulatory documents caution that the oral active ingredient should be used with care in patients who have pre-existing conditions like psoriasis or lupus erythematosus. Exacerbation (worsening) of these conditions has been reported in some cases.

Q: Does Dermoxyl interact with herbal supplements?

A: The oral active ingredient has the potential to interact with certain herbal products, such as St. John's Wort. This interaction may affect how well the medicine works in the body, potentially reducing its overall effectiveness.

Q: Does Dermoxyl contain parabens or other preservatives?

A: The list of inactive ingredients for the oral tablet form, as noted in the official FDA label, includes several common tablet components but does not list parabens as an ingredient. Specific inactive ingredients may differ between the oral tablet and the topical formulations.

Q: Are there restrictions on sun exposure while on Dermoxyl?

A: Regulatory safety information lists photosensitivity reactions as an uncommon adverse effect of the oral active ingredient. This means there is a chance of increased sun sensitivity, and patients often consult a healthcare professional regarding necessary sun exposure precautions while using this medicine.

Q: Can Dermoxyl be used for children under the age of 12?

A: Official information states that use in pediatric populations (children) is conditional and often reserved for specific indications guided by the child’s body weight. It is not routinely established for infants under 12 months, and use in children of any age requires a healthcare provider's assessment.

How should Dermoxyl be stored and disposed of?

How to Store and Dispose of Dermoxyl? — Official Regulatory Information

The official storage profile for this medication and its active ingredient requires strict adherence to temperature and environmental controls to maintain chemical stability.

Storage and Handling Requirements

Condition	Regulatory Requirement
Temperature	Store in a cool place, isolated from sunlight, and away from heat. Maximum storage temperature for the active ingredient is 40.00 C (104.00 F).
Protection	Keep containers tightly closed. Store strictly out of the sight and reach of children and pets, ideally utilizing a locking device.
Containers	Ensure all identifying information is removed from the original packaging prior to final disposal.

Disposal Instructions

The preferred method for discarding unused or expired medication is through an authorized community drug take-back program.

If a take-back program is unavailable, medication should be mixed with an undesirable substance, such as dirt or used coffee grounds, placed in a sealed container, and then discarded in the household trash. The medication must not be flushed down the sink or toilet.

Dermoxyl